Multiple Myeloma

Tandem Autologous-Allogenic HCT Offers Long-Term Remission in Multiple Myeloma

Tandem Autologous-Allogenic HCT Offers Long-Term Remission in Multiple Myeloma

By

A retrospective follow-up study demonstrates that tandem autologous-allogeneic is safe for standard and high-risk multiple myeloma. However, benefits do not extend to patients with ultra-high-risk disease and those with disease progression after autologous HCT.

Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma

Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma

By

An updated network meta-analysis found that a triplet regimen consisting of lenalidomide and dexamethasone plus an immunotherapeutic agent had better efficacy in terms of NRR, TTP, PFS, and OS than other regimens.

Clarithromycin Plus Bortezomib May Be Ineffective, Toxic in Multiple Myeloma

Clarithromycin Plus Bortezomib May Be Ineffective, Toxic in Multiple Myeloma

By

Researchers found that clarithromycin plus bortezomib does not confer any additional efficacy and is a toxic in patients with multiple myeloma.

A Novel Formulation of Melphalan May Not Prevent Complications Post-ASCT in Multiple Myeloma

A Novel Formulation of Melphalan May Not Prevent Complications Post-ASCT in Multiple Myeloma

By

High-dose melphalan is a frequently before ASCT in MM, but is associated with high rates of adverse events.

PVX-410 Vaccine May Delay Disease Progression of Smoldering Multiple Myeloma

PVX-410 Vaccine May Delay Disease Progression of Smoldering Multiple Myeloma

Reinforcing the immune system with a the PVX-410 vaccine may prevent or slow progression to multiple myeloma.

FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma

FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma

By

The manufacturer of daratumumab, a CD38-directed antibody for the treatment of multiple myeloma, has submitted a sBLA and a type II variation to the US FDA and European Medicines Agency, respectively, for approval of a split dosing regimen.

Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma

Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma

By

A prospective TLN cohort study demonstrated that trial eligibility is a strong predictor of progression-free and overall survival among patients with multiple myeloma.

No Negative Effects on HRQOL With Post-ASCT Maintenance Therapy for Multiple Myeloma

No Negative Effects on HRQOL With Post-ASCT Maintenance Therapy for Multiple Myeloma

By

Analysis of a cohort of patients with newly diagnosed multiple myeloma focused on the effect of post-ASCT maintenance therapy on health-related QOL and clinical outcomes.

Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma

Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma

By

In an analysis of 11 studies, researchers investigated whether the benefits of carfilzomib for multiple myeloma outweigh the cardiovascular risks. However, the researchers recommend careful monitoring and management of blood pressure and volume status as good clinical practice, regardless.

Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant

Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant

By

In this study, researchers investigated the effects of exercise on physical and psychological recovery after autoHSCT for multiple myeloma.

Ixazomib, Lenalidomide, Dexamethasone Effective But Increases Toxicity in Multiple Myeloma

Ixazomib, Lenalidomide, Dexamethasone Effective But Increases Toxicity in Multiple Myeloma

By

Three-drug regimen twice a week achieved good response and long-term outcomes in patients with newly diagnosed multiple myeloma; however, regimen has higher toxicity than once weekly dose.

First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma

First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma

By

The 18-month progression-free survival rate was 71.6% among patients treated with daratumumab plus VMP compared with 50.2% among patients treated with VMP alone.

Association Between Multiple Myeloma With VTE and Increased Mortality at 2, 5 Years

Association Between Multiple Myeloma With VTE and Increased Mortality at 2, 5 Years

By

A study presented at the 2018 ASCO Annual Meeting investigated the mortality risk for patients with multiple myeloma who develop VTE.

Panobinostat vs Placebo: Patient-Reported Outcomes Comparable in Multiple Myeloma

Panobinostat vs Placebo: Patient-Reported Outcomes Comparable in Multiple Myeloma

By

Investigators sought to determine the impact on quality of life for patients with relapsed/refractory multiple myeloma treated with PAN and BTZ+DEX.

RVD-Lite Has Comparable Efficacy, Improved Toxicity in Transplant-Ineligible MM

RVD-Lite Has Comparable Efficacy, Improved Toxicity in Transplant-Ineligible MM

By

In a single-arm phase 2 study, researchers explored the effectiveness of a modified lenalidomide, bortezomib, and dexamethasone (RVD-lite) regimen in transplant-ineligible patients with multiple myeloma.

Plateau-Oriented Induction Approach Inadequate in Transplant-Ineligible Multiple Myeloma

Plateau-Oriented Induction Approach Inadequate in Transplant-Ineligible Multiple Myeloma

By

In this phase 2 study, 38 patients with previously untreated multiple myeloma who were ineligible for autologous stem cell transplantation were treated with a bortezomib-containing induction regimen until plateau.

Firefighters in World Trade Center Attacks Have Increased Risk of Multiple Myeloma

Firefighters in World Trade Center Attacks Have Increased Risk of Multiple Myeloma

By

A case series demonstrates the prevalence of MGUS, a precursor condition to multiple myeloma, and subsequent development of MM in white firefighters who responded after the 9/11 attacks in New York City.

Lenalidomide Alone or With Dexamethasone Effective in Relapsed Multiple Myeloma

Lenalidomide Alone or With Dexamethasone Effective in Relapsed Multiple Myeloma

A study of 133 patients with multiple myeloma who experienced a first relapse compared the efficacy of long-term therapy lenalidomide alone vs with dexamethasone.

Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma

Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma

By

This treatment-expansion study evaluated the tolerability and safety of the PANEX (panobinostat plus bortezomib with dexamethasone) protocol in heavily treated patients with R/R multiple myeloma.

Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma

Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma

By

In a post-hoc analysis of the ASPIRE trial results, in which carfilzomib was discontinued due to a lack of long-term safety data, researchers present the safety and efficacy findings of KRd vs Rd for relapsed multiple myeloma at 18 months from randomization.

Ciprofloxacin Plus Doxycycline Reduces Infection Rate in Multiple Myeloma Post-ASCT

Ciprofloxacin Plus Doxycycline Reduces Infection Rate in Multiple Myeloma Post-ASCT

By

A health outcomes analysis of 419 patients with multiple myeloma sought to determine if cipro-doxy was more effective than cipro alone in reducing the incidence of neutropenic fever and infections, both significant causes of morbidity and death for these patients.

Bisphosphonate Therapy Underutilized in Multiple Myeloma Bone Disease Management

Bisphosphonate Therapy Underutilized in Multiple Myeloma Bone Disease Management

By

A retrospective study evaluated timing, frequency, dosing, and other factors related to bisphosphonate therapy in patients with multiple myeloma.

Pomalidomide Plus Dexamethasone Effective in R/R Multiple Myeloma

Pomalidomide Plus Dexamethasone Effective in R/R Multiple Myeloma

By

Researchers report on their findings of a retrospective study that compared pomalidomide plus dexamethasone vs dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Common Oncologic Emergencies That Occur With Multiple Myeloma

Common Oncologic Emergencies That Occur With Multiple Myeloma

By

What are the common oncologic emergencies seen in patients with MM?

Multiple Myeloma Survival Decreased With High ADAR1 RNA Expression

Multiple Myeloma Survival Decreased With High ADAR1 RNA Expression

ADAR1 knockdown reduces regeneration of high-risk multiple myeloma in patient-derived xenografts

Carfilzomib Associated With Cardiovascular Adverse Events in Multiple Myeloma

Carfilzomib Associated With Cardiovascular Adverse Events in Multiple Myeloma

By

For this meta-analysis and systematic review, investigators compiled phase 1 to 3 prospective clinical trials of carfilzomib therapy for patients with MM that had evaluable toxic effects data.

No Increased Risk for Melanoma in Patients With MM

No Increased Risk for Melanoma in Patients With MM

By

An increased prevalence of melanoma has been observed in patients with various immunocompromised conditions.

Aspirin Does Not Reduce Risk of Venous Thromboembolism in Multiple Myeloma

Aspirin Does Not Reduce Risk of Venous Thromboembolism in Multiple Myeloma

By

A retrospective study, presented at ASH 2017, determined the effectiveness of aspirin in reducing risk of VTE in patients with multiple myeloma at high risk of developing VTE.

Prolonging Survival in MM: Daratumumab vs Pomalidomide Plus Dexamethasone

Prolonging Survival in MM: Daratumumab vs Pomalidomide Plus Dexamethasone

By

A head-to-head comparison investigated whether patients with multiple myeloma achieved greater prolongation in overall survival with daratumumab monotherapy or pomalidomide plus low-dose dexamethasone.

FDA Grants Breakthrough Therapy Designation to bb2121 for Multiple Myeloma

FDA Grants Breakthrough Therapy Designation to bb2121 for Multiple Myeloma

By

Breakthrough Therapy Designation was granted for bb2121, a novel CAR T-cell therapy indicated for patients with multiple myeloma who have undergone previous treatments.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs